Futu News, March 21, announced that on Monday this week $RECBIO-B (02179.HK)$announced the public offering from March 21 to 24, the company plans to issue 30.8545 million shares, including 3.0855 million shares for public offering and 27.769 million shares for international offering, with an IPO price of HK$24.8 per share, 500 shares per board lot, expected to be listed on March 31.
Ruikang Biology is a vaccine company founded in 2012, operating primarily on a business model of independently developing new vaccines, focusing mainly on the research and development of HPV candidate vaccines.
The company has currently established a vaccine combination consisting of 12 candidate vaccines, including the core product REC603, a recombinant HPV nine-valent vaccine for cervical cancer prevention, currently in phase III clinical trials. The company has completed the recruitment of REC603 subjects and plans to complete the three-dose administration in the first half of 2022, and submit a BLA application to the national drug authority by 2025.
According to the prospectus, Ray Corp has been invested by well-known institutions such as Qingchi Capital, Temasek, Junlian Capital and Sequoia Capital.
In terms of financial data, as of now the company has not been approved for commercial sales of products, nor has it generated any revenue from vaccine sales. For the first nine months of 2019, 2020 and 2021, the company recorded comprehensive losses of RMB 0.138 billion yuan, 0.179 billion yuan, and 5.20 billion...